Press

Media Relations

If you are a journalist with a question about Lundbeck or would like to request an interview, please contact Media Relations – and we will get back to you. Please note this service is for journalists and other media professionals only. Please kindly note all other requests to this e-mail will not receive a response.

For general press enquiries, call us at +45 3643 4000

Or Write to Us

Contact Media Relations

Thomas Mikkel Mortensen

media relations lead

+ 45 30 83 30 24

LATEST RELEASES

14 September, 2023 Press Release
Lundbeck presents clinical advances in migraine prevention with positive trial results at international headache congress
07 September, 2023 Corporate Release
Lundbeck and Otsuka announce topline results from two phase III trials of brexpiprazole as combination therapy with sertraline for the treatment of Post-Traumatic Stress Disorder in adults
18 August, 2023 Press Release
Lundbeck announces changes to Executive Management

See All News

Get the latest news from Lundbeck directly in your email inbox

Subscribe to our releases

About Lundbeck

H. Lundbeck A/S (HLUNa / HLUNb, HLUNA DC / HLUNB DC) is a global pharmaceutical company specialized in brain diseases. For more than 70 years, we have been at the forefront of neuroscience research. We are tirelessly dedicated to restoring brain health, so every person can be their best.

Too many people worldwide live with brain diseases – complex conditions often invisible to others that nonetheless take a tremendous toll on individuals, families and societies. We are committed to fighting stigma and discrimination against people living with brain diseases and advocating for broader social acceptance of people with brain health conditions. Every day, we strive for improved treatment and a better life for people living with brain disease.

We have approximately 5,400 employees in more than 50 countries, and our products are available in more than 100 countries. Our research programs tackle some of the most complex challenges in neuroscience, and our pipeline is focused on bringing forward transformative treatments for brain diseases for which there are few, if any therapeutic options. We have research facilities in Denmark and the United States, and our production facilities are located in Denmark, France and Italy. Lundbeck generated revenue of DKK 18.2 billion in 2022 (EUR 2.5 billion; USD 2.6 billion).

For additional information, we encourage you to visit our corporate website www.lundbeck.com/global and connect with us via LinkedIn.

Media Library

Pictures of our Executive Management, videos, and other assets for download and distribution.

Go to Library

Communication policy

We engage in an open, constructive and continuous dialogue with our stakeholders based on equality and mutual respect.

FACTS ABOUT LUNDBECK

70 years

In the forefront of neuroscience research

100

Countries of operation around the world

5,400

Employees worldwide

18.2b DKK

Of revenue generated in 2022